REFERENCES
1. Colussi G, Da Porto A, Cavarape A. Hypertension and type 2 diabetes: lights and shadows about causality. J Hum Hypertens. 2020;34:91-3.
2. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874-2071.
3. Kario K, Hettrick DA, Prejbisz A, Januszewicz A. Obstructive sleep apnea-induced neurogenic nocturnal hypertension: a potential role of renal denervation? Hypertension. 2021;77:1047-60.
4. Fay KS, Cohen DL. Resistant hypertension in people with CKD: a review. Am J Kidney Dis. 2021;77:110-21.
5. Massi-Benedetti M. The cost of diabetes Type II in Europe the CODE-2 study. Diabetologia. 2002;45:S1-4.
6. Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. 2019;26:7-14.
7. Ruiz HH, Ramasamy R, Schmidt AM. Advanced glycation end products: building on the concept of the "common soil" in metabolic disease. Endocrinology. 2020;161:bqz006.
8. Paramasivam G, Devasia T, Jayaram A, et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. Anatol J Cardiol. 2020;23:28-34.
9. Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023;44:1313-30.
10. Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022;400:1405-16.
11. Arablinsky NA, Feshchenko DA, Shukurov FB, Vasiliev DK, Drapkina OM. Promising areas of renal denervation application. Russ J Cardiol. 2024;29:5847.
12. Aripov M, Mussayev A, Alimbayev S, Goncharov A, Zhusupova G, Pya Y. Individualised renal artery denervation improves blood pressure control in Kazakhstani patients with resistant hypertension. Kardiol Pol. 2017;75:101-7.
13. Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65:407-13.
14. Mahfoud F, Townsend RR, Kandzari DE, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol. 2021;77:2909-19.
15. Booth LC, Nishi EE, Yao ST, et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension. 2015;65:393-400.
16. Panchavinnin P, Wanthong S, Roubsanthisuk W, et al. Long-term outcome of renal nerve denervation (RDN) for resistant hypertension. Hypertens Res. 2022;45:962-6.
17. Zeijen VJM, Feyz L, Nannan Panday R, et al. Long-term follow-up of patients undergoing renal sympathetic denervation. Clin Res Cardiol. 2022;111:1256-68.
18. Sesa-Ashton G, Nolde JM, Muente I, et al. Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension. 2023;80:811-9.
19. Falkovskaya AY, Mordovin VF, Pekarsky SY, et al. Dynamics of glycemic control after renal denervation in patients with resistant hypertension and type 2 diabetes mellitus. Bull Sib Med. 2015;14:82-90.
20. Fink GD, Phelps JT. Can we predict the blood pressure response to renal denervation? Auton Neurosci. 2017;204:112-8.
21. Zhang Z, Zhang X, Ye R, Li X, Chen X. Patient preference for renal denervation therapy in hypertension: a cross-sectional survey in Chengdu, China. Hypertens Res. 2022;45:954-61.
22. Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2022;45:232-40.
23. Bartus K, Litwinowicz R, Sadowski J, et al. Clinical factors predicting blood pressure reduction after catheter-based renal denervation. Postepy Kardiol Interwencyjnej. 2018;14:270-5.
24. Sanders MF, Blankestijn PJ. Chronic kidney disease as a potential indication for renal denervation. Front Physiol. 2016;7:220.
